exactly Guzz, sarizotan only targets breathing abnormalities vs trofinetide which is potentially disease modifying thereby working across multiple symptoms. When it comes to drug pricing trofinetide would be a much higher price (and peak global sales/ market penetration much much higher) as the quality of life impact is far more substantial.
So it is clear which one would be market dominant
What will the deal be like? Head vs heart, page-51
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.20 |
Change
1.140(5.98%) |
Mkt cap ! $2.579B | |||
| Open | High | Low | Value | Volume |
| $19.58 | $20.52 | $19.47 | $9.631M | 477.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 181 | $20.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.24 | 245 | 1 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.21 |
Change
1.140 ( 5.70 %) |
||||
| Open | High | Low | Volume | ||
| $19.56 | $20.51 | $19.53 | 123739 | ||
| Last updated 15.59pm 14/05/2024 ? | |||||
| NEU (ASX) Chart |